Menu Search
Equities

Salus Ljubljana dd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0HMV:LSE

Salus Ljubljana dd

Actions
  • Price (EUR)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta0.5032
Data delayed at least 20 minutes.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Salus Ljubljana dd is a Slovenia-based company engaged in the wholesale and distribution of medical products. The Company’s portfolio includes pharmaceuticals, medical devices, medical supplies, food supplements, cosmetic products and other health products. The Company's core clients are pharmacies, hospitals and health centers from both Slovenia and abroad. Moreover, Salus Ljubljana dd offers the products to its business partners through the Internet store. The Company also provides additional services related to the registration of medicines and the distribution and storage of pharmaceuticals and other medical products.

  • Revenue in EUR (TTM)673.54m
  • Net income in EUR14.48m
  • Incorporated1974
  • Employees144.00
  • Location
    Salus Ljubljana ddLitostrojska cesta 46 ALJUBLJANA 1000SloveniaSVN
  • Phone+386 15899100
  • Fax+386 15681022
  • Websitehttps://www.salus.si/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.